NCT01640327View on ClinicalTrials.gov

Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults Aged 18 Years and Above

PHASE3CompletedINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
HumanInfluenza
Interventions
BIOLOGICAL

Trivalent influenza virus vaccine (TIVf)

A single dose (0.5 mL) of vaccine supplied in prefilled syringes was administered intramuscularly in the deltoid muscle, preferably of the non dominant arm

Trial Locations (1)

18057

University of Rostock, Department Tropical Medicine and Infectious Diseases, Rostock

Sponsors

Lead Sponsor

Novartis Vaccines
All Listed Sponsors
lead

Novartis Vaccines

INDUSTRY